Cormedix Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on January 30, 2017, reporting events occurring on that date. The filing details the appointment of two new senior executives effective February 1, 2017: Robert Cook as Chief Financial Officer and Judith Abrams as Chief Medical Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
- Base Salary: $350,000 annually for each executive.
- Annual Bonus: Up to 30% of base salary, contingent on company and personal objectives.
- Equity Grant: 350,000 stock options per executive.
- 185,000 options vest in four equal annual installments.
- 165,000 options are performance-based, split into three tranches with vesting deadlines ranging from December 31, 2017, to June 30, 2020.
- Expenses: Up to $5,000 reimbursement for legal fees and negotiation expenses per executive.
Material Changes
The primary material change is the expansion of the executive leadership team. The company has entered into three-year employment agreements (with automatic one-year renewals) for its new CFO and CMO. These agreements include specific provisions for termination benefits, including nine months of base salary continuation and accelerated vesting of time-based options under specific conditions.
Guidance, Outlook, and Risks
The filing contains no financial guidance or market outlook. Key contractual terms and risks include:
- Termination for Cause: Results in forfeiture of all unvested equity and payment of only accrued compensation.
- Termination without Cause/Good Reason: Triggers nine months of base salary continuation, prorated bonus, COBRA premium payments, and acceleration of time-based options vesting.
- Change in Control: If termination occurs within 24 months of a change in control, the executive receives nine months of base salary plus full target bonus, and all unvested options accelerate.
- Non-Compete: Executives are restricted from competing with Cormedix's anti-infective products (specifically Neutrolin or taurolidine-containing products) in the U.S. and EU for 12 months post-employment.
Investor Verification Checklist
- Verify the total number of authorized shares and the impact of the 700,000 new options (350,000 per executive) on potential dilution.
- Review the specific performance milestones for the 165,000 performance-based options per executive, as these are not detailed in this summary.
- Confirm the company's current cash position to assess its ability to fund the $700,000 combined annual base salaries and potential severance obligations.
- Examine the full employment agreements (to be filed as exhibits to the 10-K) for detailed definitions of "Cause" and "Good Reason."